Cargando…

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole

Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole. Population analyses have demonstrated relatively predictable pharmacokinetic (PK) behavior in diverse patient populations. We evaluated the impact of mucositis on the oral isavuconazole exposure using population PK modeling. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovanda, Laura L., Marty, Francisco M., Maertens, Johan, Desai, Amit V., Lademacher, Christopher, Engelhardt, Marc, Lu, Qiaoyang, Hope, William W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444187/ https://www.ncbi.nlm.nih.gov/pubmed/28289034 http://dx.doi.org/10.1128/AAC.00101-17

Ejemplares similares

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

No Dose Adjustment for Isavuconazole Based on Age or Sex
por: Desai, Amit V., et al.
Publicado: (2019)

Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
por: Kovanda, Laura L., et al.
Publicado: (2021)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
por: Desai, Amit, et al.
Publicado: (2016)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
por: Schwartz, Stefan, et al.
Publicado: (2020)

1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling
por: Desai, Amit, et al.
Publicado: (2018)

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
por: Schmitt-Hoffmann, Anne-Hortense, et al.
Publicado: (2017)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Bronchopulmonary penetration of isavuconazole in lung transplant recipients
por: Caballero-Bermejo, Antonio F., et al.
Publicado: (2023)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
por: Keirns, J, et al.
Publicado: (2017)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
por: Liu, Ya-nan, et al.
Publicado: (2023)

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
por: Hamed, Kamal, et al.
Publicado: (2023)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
por: Hamed, Kamal, et al.
Publicado: (2020)

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
por: Kaindl, Thomas, et al.
Publicado: (2019)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus
por: Al-Obaidi, Mohanad, et al.
Publicado: (2018)

Benzaldehyde, A New Absorption Promoter, Accelerating Absorption on Low Bioavailability Drugs Through Membrane Permeability
por: Wen, Wen, et al.
Publicado: (2021)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
por: Marty, Francisco M., et al.
Publicado: (2014)

Therapeutic Drug Monitoring of Isavuconazole—But What about the Critically Ill?
por: Salhotra, Ripenmeet
Publicado: (2023)

Isavuconazole as salvage therapy for mucormycosis
por: Graves, Bianca, et al.
Publicado: (2016)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Isavuconazole for invasive fungal infections
Publicado: (2020)

2110. Treatment of Coccidioidomycosis with Isavuconazole
por: Jamros, Christina, et al.
Publicado: (2019)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gorr067h4n2s498qtaordprg7h